Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera - PubMed (original) (raw)
Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera
Davide Rossi et al. Leuk Res. 2007 Jan.
Abstract
Idiopathic erythrocytosis (IE) is a primary erythrocytosis not fulfilling the criteria for polycythemia vera (PV) diagnosis. In order to verify the relationship between IE and PV, we screened JAK2V617F mutation in a consecutive series of 11 IE and, for comparison, in 15 PV. JAK2V617F mutation was screened by both cDNA sequencing and mutation specific PCR in both peripheral blood and bone marrow samples. All 11 IE tested negative for JAK2V617F mutation, which, conversely, occurred in 11/15 (73.3%) PV. Our results demonstrate that JAK2V617F is absent in IE and may represent a useful molecular marker for distinguishing IE from PV.
Similar articles
- Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V, Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND. Tutaeva V, et al. Hematology. 2007 Dec;12(6):473-9. doi: 10.1080/10245330701384005. Hematology. 2007. PMID: 17852451 - Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M, Ruggeri M, Albiero E, Madeo D, Rodeghiero F. Bernardi M, et al. Am J Hematol. 2009 Apr;84(4):258-60. doi: 10.1002/ajh.21357. Am J Hematol. 2009. PMID: 19229983 No abstract available. - Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P, Hanrahan V, Baker B, Romeril K. Ganly P, et al. Am J Hematol. 2007 Jan;82(1):80-2. doi: 10.1002/ajh.20721. Am J Hematol. 2007. PMID: 16924638 - [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E. Lengfelder E. Dtsch Med Wochenschr. 2013 Feb;138(7):331-6. doi: 10.1055/s-0032-1332856. Epub 2013 Feb 7. Dtsch Med Wochenschr. 2013. PMID: 23393003 Review. German. - Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W. Michiels JJ, et al. Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21. Pathol Biol (Paris). 2007. PMID: 16919893 Review.
Cited by
- JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation.
Sassi H, Menif S, Ammar SB, Farrah A, Othmen HBH, Amouri H. Sassi H, et al. Pan Afr Med J. 2021 Jul 12;39:194. doi: 10.11604/pamj.2021.39.194.28307. eCollection 2021. Pan Afr Med J. 2021. PMID: 34603575 Free PMC article. - Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
Roda P, Ferrari A, Tang X, Erlich P, Eisenhower C, Patel MD, Irvin-Barnwell EA. Roda P, et al. Ann Hematol. 2014 Sep;93(9):1467-72. doi: 10.1007/s00277-014-2068-2. Epub 2014 Apr 1. Ann Hematol. 2014. PMID: 24687383 Free PMC article. - JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
Yoshinaga K, Mori N, Wang YH, Tomita K, Shiseki M, Motoji T. Yoshinaga K, et al. Int J Hematol. 2008 Jul;88(1):82-87. doi: 10.1007/s12185-008-0103-6. Epub 2008 Jun 6. Int J Hematol. 2008. PMID: 18528646 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous